| This week's sponsor is RAPS. | | | |
Featured Story | | | Wednesday, July 12, 2017 The FDA has hit Ocular Therapeutix with another complete response letter. Officials at the agency again turned down Ocular’s filing for approval of postoperative pain prospect Dextenza over deficiencies in its manufacturing process. |
|
|
Top Stories Wednesday, July 12, 2017 After struggling through setbacks including stock promotion claims, the loss of CEOs and major hits to its pipeline, Galena is engaging in “extensive interactions with numerous companies" seeking “strategic alternatives” that could include a merger, a reverse merger, asset sale, combo and/or a spinoff. Wednesday, July 12, 2017 California neurodegenerative disease upstart E-Scape Bio has closed an extension of its series A round, boosting its cash to $63 million. Wednesday, July 12, 2017 Erytech Pharma has formed a collaboration with Canada’s Queen’s University to advance its drug against the rare metabolic disorder arginase-1 deficiency. The agreement enables Erytech to test its eryminase program in the inducible arginase-1 deficiency mouse model developed at Queen’s. Wednesday, July 12, 2017 A proof-of-concept study, wherein IBM's Watson supercomputer analyzed genomic data from a brain tumor, suggests that combining artificial intelligence and whole-genome sequencing could ease a "key bottleneck" in precision medicine for cancer. Tuesday, July 11, 2017 Scientists testing a meningitis shot in a mass vaccination campaign later harvested a joyfully surprising byproduct—the vaccine might also offer some protection against gonorrhea. Now, owner GlaxoSmithKline is planning to explore such potential in its MenB star Bexsero. | | | As the FDA advisory committee looks over Novartis' CAR-T med, rival Kite Pharma and its CEO Arie Belldegrun say it's the Swiss pharma's "biggest cheerleader" today. Statement Regen BioPharma says that using a focused compound library alongside its screening methodology, the biotech has identified a "dynamic new chemical compound series" that modulates NR2F6. Release Cara Therapeutics has posted summary results from its early test of oral CR845 in chronic kidney disease patients undergoing hemodialysis. Statement | |
|
Resources Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA |
